Skip to main content
Top
Published in: PharmacoEconomics 3/2002

01-12-2002 | Current Opinion

Reimbursement and Cost Containment

A German Perspective

Author: Professor Dr Friedrich Breyer

Published in: PharmacoEconomics | Special Issue 3/2002

Login to get access

Abstract

This paper distinguishes short- and long-term financing problems in social health insurance systems in Germany and other European countries. The first part focuses on recent healthcare reforms in Germany that are directed at short-term problems, in particular measures of cost containment in the pharmaceutical sector such as the introduction of a drug formulary and reforms in the system of risk adjustment to enhance competition between sickness funds. The second part discusses the likely effects of the aging of the population on the sustainability of present types of mandatory insurance coverage in Germany and possible reforms that could solve the problems. It is argued that the proposed distinction between basic and supplementary benefits requires a system of explicit rationing (e.g. by age), which determines the package of basic benefits several decades in advance.
Footnotes
1
This number cannot be interpreted as the share of wages that goes into social insurance. To obtain this share, the employer’s part of 20.6% has to be added to the gross wage. Of this total (120.6% of gross wages), 41 percentage points, or 34%, go into the social insurance system.
 
2
The last revision of this paper was in August 2002, just before the general elections of September 22, 2002.
 
3
See, for example, van de Ven and Ellis.[3] Note that in the presence of community rating, only a perfect system of risk adjustment makes high risks as attractive to the sickness funds as low risks.
 
Literature
1.
go back to reference Hjertqvist J. Meeting the challenges to European healthcare: lessons learned from the ‘stockholm Revolution’. Pharmacoeconomics 2002; 20 Suppl. 3: 47–53PubMedCrossRef Hjertqvist J. Meeting the challenges to European healthcare: lessons learned from the ‘stockholm Revolution’. Pharmacoeconomics 2002; 20 Suppl. 3: 47–53PubMedCrossRef
2.
go back to reference Turner G-M. A profile of the health sector in the United States. Pharmacoeconomics 2002; 20 Suppl. 3: 31–45PubMedCrossRef Turner G-M. A profile of the health sector in the United States. Pharmacoeconomics 2002; 20 Suppl. 3: 31–45PubMedCrossRef
3.
go back to reference Van de Ven WPMM, Ellis RP. Risk adjustment in competitive health plan markets. In: Culyer AJ, Newhouse JP, editors. Handbook of health economics. Amsterdam: North-Holland, 2000: 755–845 Van de Ven WPMM, Ellis RP. Risk adjustment in competitive health plan markets. In: Culyer AJ, Newhouse JP, editors. Handbook of health economics. Amsterdam: North-Holland, 2000: 755–845
6.
go back to reference Breyer F, Kifmann M. Optionen der Weiterentwicklung des Risikostrukturausgleichs in der GKV. DIW Discussion paper no. 236, 2001. Available from URL: http://www.diw.de Breyer F, Kifmann M. Optionen der Weiterentwicklung des Risikostrukturausgleichs in der GKV. DIW Discussion paper no. 236, 2001. Available from URL: http://​www.​diw.​de
7.
go back to reference Organisation for Economic Cooperation and Development (OECD) [editorial]. Paris: OECD Economic Outlook; No. 69. Jun 2001 Organisation for Economic Cooperation and Development (OECD) [editorial]. Paris: OECD Economic Outlook; No. 69. Jun 2001
8.
go back to reference Eurostat. Demographic Statistics 1999. Luxembourg: Office for Official Publications of the European Communities, 1999 Eurostat. Demographic Statistics 1999. Luxembourg: Office for Official Publications of the European Communities, 1999
9.
go back to reference Breyer F, Schultheiss C. ‘Primary’ rationing of health services in ageing societies: a normative analysis. Int J Health Care Finance Econ 2002; In Press Breyer F, Schultheiss C. ‘Primary’ rationing of health services in ageing societies: a normative analysis. Int J Health Care Finance Econ 2002; In Press
Metadata
Title
Reimbursement and Cost Containment
A German Perspective
Author
Professor Dr Friedrich Breyer
Publication date
01-12-2002
Publisher
Springer International Publishing
Published in
PharmacoEconomics / Issue Special Issue 3/2002
Print ISSN: 1170-7690
Electronic ISSN: 1179-2027
DOI
https://doi.org/10.2165/00019053-200220003-00009

Other articles of this Special Issue 3/2002

PharmacoEconomics 3/2002 Go to the issue

Concluding Remarks

Concluding Remarks